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was identified as an important transcriptional cofactor of PPAR￿ and is activated by SIRT1. The aim
of this study was to analyze total PGC-1￿ deficiency in an atherosclerotic mouse model. METHOD-
OLOGY/PRINCIPAL FINDINGS: To investigate if total PGC-1￿ deficiency affects atherosclerosis, we
compared ApoE(-/-) PGC-1￿(-/-) and ApoE(-/-) PGC-1￿(+/+) mice kept on a high cholesterol diet. De-
spite having more macrophages and a higher ICAM-1 expression in plaques, ApoE(-/-) PGC-1￿(-/-) did
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Abstract
Background: Atherosclerosis is a chronic inflammatory disease that evolves from the interaction of activated endothelial
cells, macrophages, lymphocytes and modified lipoproteins (LDLs). In the last years many molecules with crucial metabolic
functions have been shown to prevent important steps in the progression of atherogenesis, including peroxisome
proliferator activated receptors (PPARs) and the class III histone deacetylase (HDAC) SIRT1. The PPARc coactivator 1 alpha
(Ppargc1a or PGC-1a) was identified as an important transcriptional cofactor of PPARc and is activated by SIRT1. The aim of
this study was to analyze total PGC-1a deficiency in an atherosclerotic mouse model.
Methodology/Principal Findings: To investigate if total PGC-1a deficiency affects atherosclerosis, we compared ApoE2/2
PGC-1a2/2 and ApoE2/2 PGC-1a+/+ mice kept on a high cholesterol diet. Despite having more macrophages and a higher
ICAM-1 expression in plaques, ApoE2/2 PGC-1a2/2 did not display more or larger atherosclerotic plaques than their ApoE2/2
PGC-1a+/+ littermates. In line with the previously published phenotype of PGC-1a2/2 mice, ApoE2/2 PGC-1a2/2 mice had
marked reduced body, liver and epididymal white adipose tissue (WAT) weight. VLDL/LDL-cholesterol and triglyceride
contents were also reduced. Aortic expression of PPARa and PPARc, two crucial regulators for adipocyte differentitation and
glucose and lipid metabolism, as well as the expression of some PPAR target genes was significantly reduced in ApoE2/2
PGC-1a2/2 mice. Importantly, the epididymal WAT and aortic expression of IL-18 and IL-18 plasma levels, a pro-
atherosclerotic cytokine, was markedly reduced in ApoE2/2 PGC-1a2/2 mice.
Conclusions/Significance: ApoE2/2 PGC-1a2/2 mice, similar as PGC-1a2/2 mice exhibit markedly reduced total body and
visceral fat weight. Since inflammation of visceral fat is a crucial trigger of atherogenesis, decreased visceral fat in PGC-1a-
deficient mice may explain why these mice do not develop enhanced atherosclerosis.
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Introduction
Atherosclerosis is a chronic inflammatory disease that results
from interaction between activated endothelial cells, modified low-
density lipoproteins (LDL), monocyte-derived macrophages, T cells,
and the vessel wall. Activated endothelial cells express adhesion
molecules that attract and recruit blood monocytes and lympho-
cytes. Upon binding to the endothelial layer, these monocytes
transmigrate into the subintimal space, and differentiate into
macrophages. Plaque macrophages interact with lymphatic cells,
mainly T cells, ingest modified LDL via scavenger receptors and
become foam cells, thereby promoting plaque formation [1].
PGC-1a was the first described member of the small PGC-1
family of coactivators [2]. Other members of this protein family
are PGC-1b and PGC-related coactivator (PRC). PGC-1a is an
important cofactor in the transcriptional regulation of genes
encoding metabolic enzymes and mitochondrial proteins [3], and
it is interacting with many different transcription factors, such as
peroxisome proliferator activated receptors (PPARs, including
PPARa, PPARb/d, and PPARc), Liver X receptor a and b
(LXRa and LXRb), Glucagon receptor (GR), and Forkhead box
O1 (FoxO1) [4,5,6,7,8,9,10].
The phenotype of PGC-1a knock-out mice underlines the
central role of this transcription cofactor in homeostatic control of
metabolism: they are leaner than wild-type (WT) littermates, have
markedly reduced body fat content, and are resistant to diet-
induced obesity, hence protected from developing insulin
resistance and impaired glucose tolerance [11]. This difference is
explained by their CNS-linked hyperactivity and is not a
consequence of altered food intake [11].
Overexpression of PGC-1a in human aortic smooth muscle and
endothelial cells in vitro has been shown to prevent reactive oxygen
species (ROS) production and NAD(P)H oxidase activity, with
subsequently reduced NF-kB activity and lower expression levels
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of MCP-1 and VCAM-1 [12], which are important triggers of
inflammation and atherosclerosis. Moreover, PGC-1a overexpres-
sion in endothelial cells prevented alpha-linoleic acid-induced
ROS formation in vitro and improved endothelial dysfunction in
aortic rings ex vivo [13].
The following studies suggest a link between PGC-1a and
atherogenesis at the clinical level: Xie et al. reported a correlation
between PGC-1a polymorphism and hypertension [14], and
Zhang et al. showed an association between PGC-1a polymor-
phism and the prevalence of coronary artery disease [15].
Thus, we investigated the effects of PGC-1a deficiency on
atherogenesis by comparing ApoE2/2 PGC-1a2/2 and ApoE2/2
PGC-1a+/+ mice.
Results
Total PGC-1a2/2 deletion does not affect atherogenesis
To study the potential role of PGC-1a in atherogenesis, we
crossed PGC-1a2/2 with ApoE2/2 mice, and compared 20-week
old male ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+ mice that
were kept on a high-cholesterol diet for 12 weeks. Histomor-
phometry of thoraco-abdominal aortae stained with Oil-Red O
(ORO) revealed no difference in atherosclerotic plaque area
between ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+ mice
(Fig. 1A). Advanced plaque parameters also revealed a similar total
collagen content, plaque diameter or cap thickness in plaques of the
aortic sinus that were stained with Elastica van Gieson (Fig. 1B-F).
Increased macrophage and ICAM-1 expression in ApoE2/2
PGC-1a2/2 mice
To further analyze cellular and molecular mediators in the
progression of atherosclerosis, we quantified the amount of lipids,
macrophages, T cells, as well as of the adhesion molecules ICAM-
1 and VCAM-1 in plaques from the aortic sinus. No difference in
lipid content, CD3-positive T cells, and VCAM-1 expression was
observed between ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+
mice. However, more CD68-positive macrophages and ICAM-1-
Figure 1. Atherosclerotic lesions and features of plaque vulnerability in ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+ mice. En face
plaque quantification of thoraco-abdominal aortae stained with ORO (A). Absolute values of plaque collagen content (B), necrotic core size (C) and
cap thickness (D) in plaques from the aortic sinus. Relative values of the necrotic core and fibrous cap size on plaque diameter (E), and representative
images to show how the necrotic core (blue line) and fibrous cap (black line) in plaques from the aortic sinus was measured (F). A: ApoE2/2 PGC-1a+/+
n= 13 (open circles); ApoE2/2 PGC-1a2/2 n=14 (closed circles). B-E: n = 10. ApoE2/2 PGC-1a2/2 (2/2) and ApoE2/2 PGC-1a+/+ (+/+).
doi:10.1371/journal.pone.0013539.g001
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expressing cells were detected in plaques from ApoE2/2 PGC-1a2/2
mice (Fig. 2).
ApoE2/2 PGC-1a2/2 mice exhibit reduced total body
weight, epididymal white adipose tissue weight, and
VLDL/LDL-cholesterol and VLDL/LDL-triglyceride
contents
ApoE2/2 PGC-1a2/2 mice had a lower body, liver, and
epididymal fat weight than ApoE2/2 PGC-1a+/+ mice (Fig. 3A–
D). Spleen weight did not differ between the two groups (Fig. 3E).
These data match the published phenotype of PGC-1a2/2 mice
[11]. We next analyzed total cholesterol and triglyceride plasma
levels and their distribution in lipoprotein fractions. Both
cholesterol and triglyceride contents were lower in VLDL and
IDL/LDL particles, whereas their content in HDL particles did
not differ (Fig. 4A, B). Total plasma cholesterol showed a clear
trend, whereas total triglyceride levels were markedly lower in
ApoE2/2 PGC-1a2/2 compared to ApoE2/2 PGC-1a+/+ mice
(Fig. 4C).
Reduced expression of PPAR and PPAR target genes
Peroxisome proliferator activated receptors (PPARs) are impor-
tant regulators of adipocyte differentiation as well as lipid
metabolism and inflammation and their transcription is regulated
by PGC-1a [6,16,17]. mRNA expression PPARa and PPARc was
reduced in aortic lysates of ApoE2/2 PGC-1a2/2 mice (Fig. 5A),
whereas PPARb/d levels were not changed (Fig. 5A). To examine
if the differential expression of these transcriptional regulators
exert functional effects, we quantified the expression of some
PPARa and/or PPARc target genes: Adipoq (adiponectin), Cebpa (C/
EBP-a), Fabp4 (aP2), Fasn (Fatty acid synthase), Fatp1 (Fatty acid
transport protein 1), Lipe (Hormone-sensitive lipase), Lpl (Lipoprotein lipase),
Figure 2. Characterization of plaque inflammation. Quantitative analysis of lipid content in aortic sinus (A; Oil red-O staining), macrophage
immunoreactivity (B; CD68-positive cells), T cell number (C; CD3-positive cells; scale bar, 200 mm), VCAM-1 (D) and ICAM-1 (E) immunoreactivity in
plaques of the aortic sinus of ApoE2/2 PGC-1a2/2 (2/2) and ApoE2/2 PGC-1a+/+ (+/+) mice expressed as a proportion of the total plaque areas. n = 10
per genotype. * p,0.05. **p,0.01.
doi:10.1371/journal.pone.0013539.g002
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LXR-a (Liver X receptor a), Pck1 (Phosphoenolpyruvate carboxykinase 1),
and Ucp1 (Uncoupling protein 1). Expression of Cebpa, Fabp4, Pck1,
and Ucp1 was significantly lower in ApoE2/2 PGC-1a2/2
compared to ApoE2/2 PGC-1a+/+ mice, while the expression of
Fasn showed the same trend and mRNA levels of Adipoq, Fatp1,
Lipe, Lpl, and LXR-a did not differ (Fig. 5B). These data suggest
that PPARa and PPARc expression and function may at least in
part be suppressed in ApoE2/2 PGC-1a2/2 mice.
Expression of IL-18 in epididymal WAT from ApoE2/2
PGC-1a2/2 mice is markedly reduced
Mice transplanted with visceral fat develop more atherosclerosis
than sham-operated animals [18], supporting the clinical concept
that that visceral fat as well as its inflammatory mediators are an
important risk factors of atherosclerosis and acute coronary events
[19,20]. We therefore analyzed the expression of adipose tissue-
derived hormones and cytokines in ApoE2/2 PGC-1a2/2 and
ApoE2/2 PGC-1a+/+ mice. While expression of Adipoq, Nampt
(Nicotinamide phosphoribosyltransferase), Retn (Resistin), IL-6, IL-10,
TGF-b, MCP-1, IFN-c, Agt (Angiotensinogen), 11b-HSD1 (11-beta-
hydroxysteroid dehydrogenase 1), TNFa, and Lpl was only mildly reduced
or unchanged, the expression of leptin, Rarres2 (chemerin), Serpine1
(PAI-1), and IL-18 was lower, and expression of complement factor D
(Cfd or adipsin) higher in ApoE2/2 PGC-1a2/2 compared to
ApoE2/2 PGC-1a+/+ epididymal WAT (Fig. 6).
Reduced expression of IL-18 and CXL16 in aortic lysates
from ApoE2/2 PGC-1a2/2 mice
The reduced expression of IL-18 in epididymal WAT is of
special interest, since ApoE2/2 IL-182/2 mice develop less
atherosclerosis than control ApoE2/2 mice [21]. Importantly,
injection of IL-18 into SCID/apoE kockout mice elevated levels of
Figure 3. Total body weight and adipose tissue mass. ApoE2/2 PGC-1a2/2 exhibit a lower body weight (A), liver weight (B), as well as total
epididymal (C) and percent epididymal fat of body weight (D) than ApoE2/2 PGC-1a+/+ mice. No difference is observed in spleen weight (E). n$14 per
genotype. * p,0.05; *** p,0.001.
doi:10.1371/journal.pone.0013539.g003
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IFN-c and scavenger receptor for phosphatidylserine and oxidized
lipoprotein/CXC chemokine ligand 16 (SR-PSOX/CXCL16) in
atherosclerotic lesions [22]. Measurement of these factors in aortic
tissue, revealed that IL-18 and SR-PSOX/CXCL16 mRNA levels
were reduced in ApoE2/2 PGC-1a2/2mice, while IFN-c expression
did not differ between the two genotypes (Fig. 7A). We also
quantified the amount of IL-18 and soluble SR-PSOX/CXCL16 in
plasma samples. In line with the reduced expression in epididymal
WAT and aortae, IL-18 protein level was also reduced in the plasma
of ApoE2/2 PGC-1a2/2 compared to ApoE2/2 PGC-1a+/+ mice
(Fig. 7B). In contrast, plasma levels of secreted SR-PSOX/CXCL16
did not differ between the two genotypes (Fig. 7B).
Discussion
Our data show that ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-
1a+/+ mice do not differ with regard to atherosclerosis, features of
plaque vulnerability, expression of VCAM-1, and T cells number.
Increased expression of ICAM-1 or CD68-positive cells in plaques
of ApoE2/2 PGC-1a2/2 do not appear to play a substantial role as
they do not affect plaque size. Importantly, the double knockout
mice are leaner, have lighter liver and epididymal fat, and less
cholesterol and triglycerides in VLDL and LDL subfractions. In
addition, aortic expression of PPARa and PPARc as well as some of
their target genes is reduced in ApoE2/2 PGC-1a2/2 mice.
This phenotype is in line with the first study that described the
phenotype of PGC-1a2/2 mice, which also have markedly reduced
body fat content [11]. Because visceral (epididymal) WAT
inflammation contributes to disease progression [18], it is not
astonishing that we observed no difference in plaque lesions
between ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+ mice.
Beyond this notion, our data propose that total PGC-1a deficiency
may rescue an increased atherosclerotic phenotype because of the
reduced paracrine effects mediated by the visceral fat.
The lower aortic expression of PPARa and PPARc as well as of
PPAR target genes proposes that the function of these two PPARs is
suppressed in ApoE2/2 PGC-1a2/2 mice. Interestingly, both
PPARa and PPARc can exert anti-atherogenic functions in the
Figure 4. Plasma lipid levels. (A, B) Cholesterol and triglyceride
distribution in the plasma lipoprotein fractions of ApoE2/2 PGC-1a2/2
and ApoE2/2 PGC-1a+/+ mice. Plasma samples were pooled (n = 14 per
genotype) and fractionated on a HPLC column. (C) Total cholesterol and
triglycerides concentrations were measured with an enzymatic color-
imetric assay. n = 14 per genotype. HPLC, high pressure liquid
chromatography; HDL, high-density lipoproteins; IDL, intermediate-
density lipoproteins; LDL, low-density lipoproteins; VLDL, very-low-
density lipoproteins. ** p,0.01.
doi:10.1371/journal.pone.0013539.g004
Figure 5. Expression of PPAR and PPAR target genes. (A) Reduced
aortic mRNA expression of PPARa and PPARc, but unchanged expression
of PPARb/d in ApoE2/2 PGC-1a2/2 compared to ApoE2/2 PGC-1a+/+ mice.
(B) Aortic mRNA expression of Adipoq, Cebpa, Fabp4, Fasn, Fatp, Lipe, Lpl,
LXR-a, Pck1, and Ucp1. n$9 per genotype. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0013539.g005
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arterial wall. For example, administration of the PPARc ligand
rosiglitazone reduces foam cell formation and atherosclerosis in
LDL-R knockout mice [23], and transplantation of PPARc-deficient
bone marrow into recipient LDL-R knockout mice enhanced
atherosclerosis [24]. One of the main atherogenic targets of PPARc
is LXRa [24,25], whose expression was not changed between
ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+ aortic lysates.
Reduced expression of Rarres2 (chemerin), Serpine1 (PAI-1), and IL-
18 in visceral adipose tissue could be sufficient to avoid increased
atherogenesis. Rarres2 is associated with white adipose tissue
inflammation and promotes mobilization and chemotaxis of
dendritic cells and macrophages [26,27]. While its expression
correlates with inflammatory markers, such as C-reactive protein,
it does not predict atherosclerosis in humans [28]. Nevertheless, an
atherogenic contribution of Rarres2 cannot be excluded.
PAI-1 is an anti-fibrinolytic enzyme and has beneficial and
deleterious effects in atherogenesis. For example, PAI-1-deficient
mice showed attenuated neointima formation after perivascular
cuff-induced injury [29], and local PAI-1 overexpression prevented
the development of abdominal aortic aneurysm [30]. On the other
hand, PAI-1 levels are elevated in various cardiovascular diseases
and associated with atherothrombosis [31].
The lowest expression of the tested cytokines in the visceral WAT
of ApoE2/2 PGC-1a2/2 mice was observed for IL-18. IL-18 is a
pro-atherogenic cytokine: Overexpression of IL-18 binding protein
and direct injection of recombinant IL-18 accelerate atherogenesis,
whereas IL-18 deficiency diminishes plaque formation in ApoE2/2
mice [21,22,32,33]. Furthermore, elevated levels of plasma IL-18
are observed in patients with previous myocardial infarction and are
associated with the extent of coronary atherosclerosis [34,35]. We
did not only observe a reduced expression of IL-18 in epididymal
WAT, but also in aortic tissue and plasma samples of ApoE2/2 PGC-
1a2/2 mice. It is conceivable that the lower expression of IL-18
alone is sufficient to avoid an acceleration of atherogenesis in our
ApoE2/2 PGC-1a2/2 mouse model.
Interestingly, IL-18-mediated increase of atherosclerosis is accom-
panied by elevation of SR-PSOX/CXCL16 expression [22]. SR-
PSOX/CXCL16 is a membrane-bound scavenger receptor that
binds to the chemokine (C-X-C motif) receptor 6 on lymphocytes
[36,37,38,39]. This membrane-anchored chemokine can be further
cleaved by specific proteases, hence released in a soluble form
[40,41], which has been proposed as a biomarker for acute coronary
syndromes [42]. We observed reduced mRNA levels of SR-PSOX/
Figure 6. Expression of adipocyte-derived hormones and adipokines. Epididymal WAT mRNA expression in ApoE2/2 PGC-1a2/2 and
ApoE2/2 PGC-1a+/+ mice: Adipoq, Leptin, Nampt, Rarres2, Retn, Serpine1, IL-6, IL-10, IL-18, TGFb, MCP-1, Cfd, IFN-c, Agt, 11b-HSD1, TNFa and Lpl.
n = 11 per genotype. * p,0.05; 1 p,0.01, & p,0.001.
doi:10.1371/journal.pone.0013539.g006
Figure 7. Aortic and plasma expression levels of IL-18 and
CXCL16. (A) Reduced aortic mRNA expression of IL-18 and CXCL16, but
no change in the expression of IFN-c is observed in ApoE2/2 PGC-1a2/2
compared to ApoE2/2 PGC-1a+/+ mice. n$9 per genotype. (B) In plasma
samples only IL-18, but not CXCL16 protein levels differed between
ApoE2/2 PGC-1a2/2 and ApoE2/2 PGC-1a+/+ mice. n$10 per genotype.
* p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0013539.g007
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CXCL16 in epididymal WAT and aortae of ApoE2/2 PGC-1a2/2
mice. However, protein levels of the soluble form of SR-PSOX/
CXCL16 in plasma did not differ between ApoE2/2 PGC-1a2/2 and
ApoE2/2 PGC-1a+/+ mice, suggesting that the proteolytic cleavage of
this chemokine is not affected in ApoE2/2 PGC-1a2/2 mice.
Cfd encodes adipsin, the mouse homolog of human complement
factor D, which is a serine protease that cleaves factor B in the
alternative complement pathway, and it is secreted at high levels in
adipose tissue [43,44,45]. While adipsin expression is increased in
catabolic conditions such as fasting, it is down-regulated in
different models of genetic and acquired obesity [46]. In line with
these observations, epididymal WAT expression of adipsin was
higher in ApoE2/2 PGC-1a2/2 compared to ApoE2/2 PGC-1a+/+
mice. Expression of adipsin and other components of the
alternative complement pathway correlate with atherosclerosis
[47], suggesting that the elevation of adipsin in ApoE2/2 PGC-
1a2/2 provides a pro-atherogenic contribution.
Atherosclerosis is a disease combining the complexity of lipid/
lipoprotein and inflammatory/immune disorders [48]. Since
PGC-1a is affecting these two important atherogenic systems, it
is difficult to dissect the functions of this enzyme in the chosen
animal model. For example, the reduced body weight and VLDL/
LDL-cholesterol and triglyceride contents as well as the dimin-
ished expression of IL-18 are certainly anti-atherogenic, whereas
the increased expression of adipsin may play a pro-atherogenic
role in ApoE2/2 PGC-1a2/2 mice. Further studies using tissue-
specific PGC-1a knockout or overexpression will be necessary to
address these questions in more detail.
Materials and Methods
Animals
ApoE2/2C57BL/6 [49]mice were crossed to PGC-1a2/2C57BL/
6 [11], to generate ApoE2/2 PGC-1a2/2 mice and ApoE2/2 PGC-
1a+/+ littermates. Of those, male mice were fed a high-cholesterol diet
(D12108: 40 kcal% fat, 1.25% cholesterol, Research Diets Inc.) for 12
weeks starting at the age of 8 weeks. Mice were weighted before being
sacrificed, and biopsies of aortae, heart, liver, spleen, brown and white
adipose tissue, and pancreas frozen in liquid nitrogen or OCT
(Optimal Cutting Temperature) for later analyses.
Ethics Statement
All animal procedures were approved by the local animal
committee (Kantonales Veterina¨ramt Zu¨rich, protocol no. 171/
2006) and performed in accordance with our institutional guidelines.
Immunohistochemistry
5 mm serial cryosections from the aortic sinus were stained with
rat anti-CD68, rat anti-CD3 (Abcam), rat anti-VCAM-1 (BD
Biosciences), rat anti-ICAM-1 (Serotec), or oil-red O (ORO).
Thoraco-abdominal aortae were fixed with 4% paraformaldehyde
and plaques stained with ORO for en face analysis. Collagen,
fibrous cap thickness, and necrotic core size were analyzed on
Elastica van Gieson (EVG)-stained cryosections of the aortic sinus
as described [50,51]. Means were taken from n= 10 different mice
evaluating 6 serial cryosections/tissue from each mouse.
RNA and protein analysis
Total RNA isolated from proximal aortae was extracted with
TRIZOL (Invitrogen), reverse transcribed with Ready-To-Go
You-Prime First-Strand Beads (GE Healthcare), and the cDNA
(n$9 per genotype) quantified by qPCR using SYBR Green
JumpStart Taq ReadyMix (Sigma-Aldrich). Primer sequences can
be found in the supplemental Table S1.
IL-18 and CXCL16 ELISA
Quantification of IL-18 and CXCL16 in plasma of mice where
performed with Mouse IL-18 Platinum ELISA kit (Bender
MedSystems) and Mouse CXCL16 ELISA kit (RayBiotech)
according to the manufacturers instructions. Plasma was diluted
1:2 for the IL-18, and 1:32 for the CXCL16 ELISA assay.
Cholesterol, triglycerides, and lipoprotein subfractioning
Total plasma cholesterol and triglycerides were quantified using
Infinity Cholesterol TR13421 and Infinity Triglycerides TR22421
(Thermo Electron Cooperation), respectively. The lipid distribu-
tion in plasma lipoprotein fractions was assessed by fast-
performance liquid chromatography gel filtration with a Tricorn
Superose 6 10/300 GL column (GE Healthcare) [52].
Statistical analyses
Data are presented as mean 6 SEM. The en face ORO
quantification was analyzed using a non-parametric Mann-
Whitney U t-test. Statistical significance of differences of all other
experiments was calculated using an unpaired Student’s t-test.
Significance was accepted at the level of p,0.05.
Supporting Information
Table S1 Primer sequences.
Found at: doi:10.1371/journal.pone.0013539.s001 (0.08 MB
PDF)
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